Apollon Formularies Plc Result of General Meeting
11 April 2023 - 11:00PM
UK Regulatory
TIDMAPOL
11 April 2023
Apollon Formularies Plc
Result of GM
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK-based
international medical cannabis pharmaceutical company specialising in cutting
edge research and treatment of patients with various conditions including
cancer, chronic pain and epilepsy, is pleased to announce that following the
Company's General Meeting held on 11 April 2023, all resolutions were duly
passed.
As announced on 21 March 2023, the 28-day due diligence period extended to
Global Hemp Group is expected to conclude on 28 April 2023. A further
announcement will be made in due course.
The Asset disposal circular remains available at https://apollon.org.uk/.
The Directors of the Company accept responsibility for the contents of this
announcement.
-ENDS-
For additional information, please visit www.apollon.org.uk or contact:
Apollon Formularies
Tel: +44 771 198 0221
Stene Jacobs stene@apollon.org.uk
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller gm@peterhousecapital.com
BlytheRay (Financial PR/IR-London)
Tel: +44 207 138 3204
Tim Blythe/Megan Ray apollon@blytheray.com
About Apollon Formularies and Apollon Formularies Jamaica
Apollon Formularies plc is an international medical cannabis and medicinal
mushroom pharmaceutical company headquartered in the United Kingdom. Apollon
Formularies Jamaica Limited is a pharmaceutical company incorporated and
operating in the Commonwealth of Jamaica since 2016. Apollon Jamaica is
licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to
cultivate, perform research and development, process, and sell therapeutic
products that include legal medical cannabis to treat various illnesses under
medical supervision.
Apollon's proprietary medical cannabis formulations have undergone third-party
testing which demonstrated the successful killing of nearly 100% of prostate,
triple negative and HER2+ breast cancer cells in 3D cell cultures. Apollon's
products are also used to treat patients suffering from different conditions,
including chronic pain and epilepsy.
END
(END) Dow Jones Newswires
April 11, 2023 09:00 ET (13:00 GMT)
Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From May 2024 to Jun 2024
Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Jun 2023 to Jun 2024